GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction.

作者信息

Mocciaro Gabriele, Capodici Angelo, De Amicis Ramona

机构信息

Roger Williams Institute of Liver Studies, Foundation for Liver Research, London, UK.

Health Science Interdisciplinary Center, Sant'Anna School of Advanced Studies, 56127 Pisa, Italy, Pisa, Italy.

出版信息

BMJ Nutr Prev Health. 2025 Mar 3;8(1):e001206. doi: 10.1136/bmjnph-2025-001206. eCollection 2025.

DOI:10.1136/bmjnph-2025-001206

PMID:40771503

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12322565/

Abstract

摘要

相似文献

[1]

GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction.

BMJ Nutr Prev Health. 2025-3-3

[2]

Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.

Mol Metab. 2024-2

[3]

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

Metabolism. 2025-3

[4]

Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.

J Obes. 2025-7-24

[5]

"Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.

Aesthet Surg J Open Forum. 2025-6-11

[6]

Preoperative optimization of obese spine patients with GLP-1 receptor agonists: enhancing surgery and improving outcomes.

J Spine Surg. 2025-6-27

[7]

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.

J Diabetes. 2025-8

[8]

GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies.

Diabetes Metab. 2025-9

[9]

Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.

Diabetes Obes Metab. 2024-9

[10]

Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.

Calcif Tissue Int. 2024-2

本文引用的文献

[1]

Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.

Diabetes Obes Metab. 2024-12

[2]

Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity.

Obes Rev. 2025-1

[3]

On the pathogenesis of obesity: causal models and missing pieces of the puzzle.

Nat Metab. 2024-10

[4]

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.

Nat Metab. 2024-10

[5]

Understanding the cause of type 2 diabetes.

Lancet Diabetes Endocrinol. 2024-9

[6]

Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.

Diabetes Obes Metab. 2024-9

[7]

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.

Diabetologia. 2024-11

[8]

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.

N Engl J Med. 2021-5-6

[9]

Very low calorie ketogenic diets in overweight and obesity treatment: Effects on anthropometric parameters, body composition, satiety, lipid profile and microbiota.

Obes Res Clin Pract. 2020

[10]

Exercise and metabolic health: beyond skeletal muscle.

Diabetologia. 2020-8

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献